| Literature DB >> 36154101 |
Jorge González-Rodríguez1, Jesús Albarrán-Velo1, Raquel G Soengas1, Iván Lavandera1, Vicente Gotor-Fernández1, Humberto Rodríguez-Solla1.
Abstract
A bienzymatic cascade has been designed and optimized to obtain enantiopure chlorohydrins starting from the corresponding 1-aryl-2-chlorobut-2-en-1-ones. For the synthesis of these α-chloroenones, a two-step sequence was developed consisting of the allylation of the corresponding aldehyde with 3-dichloroprop-1-ene, followed by oxidation and further isomerization. The selective cooperative catalytic system involving ene-reductases (EREDs) and alcohol dehydrogenases (ADHs) afforded the desired optically active chlorohydrins under mild reaction conditions in excellent conversions (up to >99%) and selectivities (up to >99:1 diastereomeric ratio (dr), >99% enantiomeric excess (ee)).Entities:
Mesh:
Substances:
Year: 2022 PMID: 36154101 PMCID: PMC9552227 DOI: 10.1021/acs.orglett.2c02592
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.072
Scheme 1Proposed Bienzymatic Reduction Cascade of 1-Aryl-2-chlorobutan-1-ols
Scheme 2Synthesis of α-Chloroenones 1a–g
ERED-Catalyzed Bioreduction of Chloroenone 1aa
| entry | ERED | ||
|---|---|---|---|
| 1 | 103 | 89 | 88 ( |
| 2 | 110 | 99 | 94 ( |
| 3 | 112 | 7 | n.d. |
| 4 | 207 | 88 | 92 ( |
| 5 | P1-A04 | >99 | 78 ( |
| 6 | P1-E01 | 72 | 77 ( |
| 7 | P1-H09 | 78 | 85 ( |
For further details, see Table S1.
Determined by GC.
Determined by HPLC. Major enantiomer in parentheses. n.d.: not determined.
Figure 1Role of the cosolvent (5% vol) in the ERED–110-catalyzed bioreduction of 1a (25 mM, KPi buffer, pH 7, 30 °C, 4 h, 250 rpm).
Optimization of ERED–110-Catalyzed Bioreduction of Chloroenone 1a to Obtain (R)-2a
| entry | 2-PrOH (% vol) | ||||
|---|---|---|---|---|---|
| 1 | 2.5 | 30 | 4 | 90 | 91 |
| 2 | 5.0 | 30 | 4 | 97 | 93 |
| 3 | 7.5 | 30 | 4 | 83 | 94 |
| 4 | 10.0 | 30 | 4 | 86 | 94 |
| 5 | 5.0 | 25 | 4 | >99 | 97 |
| 6 | 5.0 | 25 | 3 | >99 | 98 |
| 7 | 5.0 | 25 | 2 | 94 | 95 |
For further details, see Tables S5 and S6.
Determined by GC.
Determined by HPLC.
Screening of ADHs Combined with the Selected EREDs for the One-Pot Cascade Bioreduction of 1aa
| entry | ERED | ADH | ||||
|---|---|---|---|---|---|---|
| 1 | 110 | >99 | 99:1 | 98 (1 | n.d. | |
| 2 | 110 | 98 | 96:4 | 98 (1 | n.d. | |
| 3 | 110 | ADH-T | >99 | >99:1 | 96 (1 | n.d. |
| 4 | 110 | ADH-A | >99 | 98:2 | 93 (1 | n.d. |
| 5 | 110 | evo.1.1.200 | >99 | <1:>99 | n.d. | >99 (1 |
| 6 | 110 | KRED-P2-D03 | >99 | <1:>99 | n.d. | 99 (1 |
| 7 | 110 | KRED-P3-B03 | >99 | >99:<1 | 91 (1 | n.d. |
| 8 | P1-H09 | >99 | >99:<1 | 85 (1 | n.d. | |
| 9 | P1-H09 | 90 | >99:<1 | 92 (1 | n.d. |
For further details, see Table S9.
Determined by GC.
Determined by HPLC. Major diastereoisomer in parentheses. n.d.: not determined.
Scheme 3Scope of the Bienzymatic ERED–ADH System towards the Synthesis of Optically Active Chlorohydrins 3b–g